HypertensionPhase 3NCT00095550

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

A Phase 3 study testing Irbesartan/HCTZ, Irbesartan monotherapy and HCTZ monotherapy in people with Hypertension, run by Bristol-Myers Squibb at 128 sites in 5 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Hypertension
What is being tested?: Irbesartan/HCTZ, Irbesartan monotherapy and HCTZ monotherapy
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 496 participants
Where: 128 sitesin 5 countries
Study dates: Oct 2004to Jun 2005
Phase: Phase 3
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Willing to provide written informed consent
Subjects must have uncontrolled hypertension defined as:
average systolic blood pressure between 160 mmHg and 180 mmHg (while diastolic blood pressure is less than 110 mmHg) or
average diastolic blood pressure between 100 mmHg and 110 mmHg (while systolic blood pressure is between 130 mmHg and 180 mmHg)
Subjects must be willing to discontinue their antihypertensive medication, if applicable.
Men and women, ages 18 and older will be included.
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication.

Who cannot join

Women who are pregnant or breastfeeding
Known or suspected secondary hypertension
Hypertension emergencies or stroke within the past 12 months.
Heart attack, angina or bypass surgery within the past six months.
Significant kidney disease
Significant liver disease

Show all 13Show fewer

Systemic lupus erythematosus
Gastrointestinal disease or surgery that interfere with drug absorption
Cancer during the past five years excluding localized squamous cell or basal cell carcinoma of the skin
Currently pregnant or lactating
Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope, and possible consequences of the study
Drug or alcohol abuse within the last five years
Known allergy to irbesartan or diuretics

Trial locations and contacts

128 sites in 5 countries.

Country

City, postcode or hospital

128 sites in 5 countries

United States87 sites

Local Institution
Atlanta, Georgia
Local Institution
Austin, Texas
Local Institution
Baltimore, Maryland
Local Institution
Bartlett, Tennessee
Local Institution
Bensalem, Pennsylvania
Local Institution
Birmingham, Alabama
Local Institution
Bridgeport, Connecticut
Local Institution
Buffalo, New York
Local Institution
Camp Hill, Pennsylvania
Local Institution
Canton, Ohio
Local Institution
Carmichael, California
Local Institution
Chalmette, Louisiana
Local Institution
Charleston, South Carolina
Local Institution
Charlotte, North Carolina
Local Institution
Charlottesville, Virginia
Local Institution
Chicago, Illinois
Local Institution
Chipley, Florida
Local Institution
Cincinnati, Ohio
Local Institution
Clearwater, Florida
Local Institution
Collegeville, Pennsylvania
Local Institution
Colleyville, Texas
Local Institution
Columbia, South Carolina
Local Institution
Columbiana, Alabama
Local Institution
Crestview, Florida
Local Institution
DeLand, Florida
Local Institution
Dover, New Hampshire
Local Institution
Eugene, Oregon
Local Institution
Fair Oaks, California
Local Institution
Fresno, California
Local Institution
Gastonia, North Carolina
Local Institution
Genoa, Ohio
Local Institution
Greensboro, North Carolina
Local Institution
Hendersonville, Tennessee
Local Institution
Highlands Ranch, Colorado
Local Institution
Hollywood, Florida
Local Institution
Jacksonville, Florida
Local Institution
Kettering, Ohio
Local Institution
Levittown, Pennsylvania
Local Institution
Livonia, Michigan
Local Institution
Long Beach, California
Local Institution
Lyndhurst, Ohio
Local Institution
Madison, Wisconsin
Local Institution
Medford, Oregon
Local Institution
Mesa, Arizona
Local Institution
Miami, Florida
Local Institution
Midland, Texas
Local Institution
Milwaukee, Wisconsin
Local Institution
Mint Hill, North Carolina
Local Institution
Missoula, Montana
Local Institution
Mount Vernon, New York
Local Institution
Nashville, Tennessee
Local Institution
New Orleans, Louisiana
Local Institution
New York, New York
Local Institution
Newark, Delaware
Local Institution
Niceville, Florida
Local Institution
Ocoee, Florida
Local Institution
Oklahoma City, Oklahoma
Local Institution
Olive Branch, Mississippi
Local Institution
Olympia, Washington
Local Institution
Orangeburg, South Carolina
Local Institution
Oxon Hill, Maryland
Local Institution
Pembroke Pines, Florida
Local Institution
Penndel, Pennsylvania
Local Institution
Peoria, Illinois
Local Institution
Philadelphia, Pennsylvania
Local Institution
Phoenix, Arizona
Local Institution
Portland, Oregon
Local Institution
Rolling Hills Estate, California
Local Institution
Roseville, California
Local Institution
Sacramento, California
Local Institution
Saginaw, Michigan
Local Institution
Saint Cloud, Florida
Local Institution
Salt Lake City, Utah
Local Institution
San Antonio, Texas
Local Institution
San Jose, California
Local Institution
Selmer, Tennessee
Local Institution
Simpsonville, South Carolina
Local Institution
South Bound Brook, New Jersey
Local Institution
Spokane, Washington
Local Institution
Springfield, Massachusetts
Local Institution
Summerville, South Carolina
Local Institution
The Bronx, New York
Local Institution
Torrance, California
Local Institution
Tustin, California
Local Institution
Waterbury, Connecticut
Local Institution
West Grove, Pennsylvania
Local Institution
Winston-Salem, North Carolina

Other trials in United States

Canada22 sites

Local Institution
Aylmer, Ontario
Local Institution
Burlington, Ontario
Local Institution
Coquitlam, British Columbia
Local Institution
Drummondville, Quebec
Local Institution
Greenfield Park, Quebec
Local Institution
Halifax, Nova Scotia
Local Institution
Hamilton, Ontario
Local Institution
Markham, Ontario
Local Institution
Montague, Prince Edward Island
Local Institution
North Vancouver, British Columbia
Local Institution
Oakville, Ontario
Local Institution
Oshawa, Ontario
Local Institution
Red Deer, Alberta
Local Institution
Richmond Hill, Ontario
Local Institution
Saint-Lambert, Quebec
Local Institution
Sarnia, Ontario
Local Institution
Saskatoon, Saskatchewan
Local Institution
Sidney, British Columbia
Local Institution
St. John's, Newfoundland and Labrador
Local Institution
Thornhill, Ontario
Local Institution
Toronto, Ontario
Local Institution
Winnipeg, Manitoba

Other trials in Canada

Germany12 sites

Local Institution
Berlin
Local Institution
Essen
Local Institution
Feldafing
Local Institution
Grömitz
Local Institution
Künzing
Local Institution
Nörten-Hardenberg
Local Institution
Nuremberg
Local Institution
Ornbau
Local Institution
Spaichingen, Baden-Wurttembe
Local Institution
Spaichingen, Braden-Wurttembe
Local Institution
Unterschneidheim
Local Institution
Villingen-Schwenningen

Other trials in Germany

France4 sites

Local Institution
Angers
Local Institution
Bouchemaine
Local Institution
Briollay
Local Institution
Tiercé

Other trials in France

Russia3 sites

Local Institution
Moscow
Local Institution
Saint Petersburg
Local Institution
Saratov

Other trials in Russia

About this study

Official title: The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension

Conditions: Hypertension
Being tested: Irbesartan/HCTZ, Irbesartan monotherapy, HCTZ monotherapy
Keywords: Moderate Hypertension
Medical subject headings: Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Irbesartan/HCTZDrug
Also called Avapro
Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
Irbesartan monotherapyDrug
Also called Avapro
Tablets, Oral, 150 mg, Once daily, 12 weeks.
HCTZ monotherapyDrug
Tablets, Oral, 12.5 mg, Once daily, 12 weeks.

Study groups in NCT00095550
Study group	Role	What they receive
A1	Experimental	Not described Receives: Drug: Irbesartan/HCTZ
A2	Active comparator	Not described Receives: Drug: Irbesartan monotherapy
A3	Active comparator	Not described Receives: Drug: HCTZ monotherapy

What is being measured

The primary outcome is the main question the study is designed to answer.

Change from baseline in SeSBP at Week 8

Secondary outcomes (1)

Frequency of discontinuation due to AE, frequencies of hypotension, dizziness, syncope, headaches, hypokalemia and hyperkalemia after 12 weeks of therapy.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Oct 2004Jun 2005

First posted8 Nov 2004 (estimated)
Study startOct 2004
Primary completionJun 2005
Study completionJun 2005

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for HypertensionStudies of the same condition, open and under way.
More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 496 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00095550
Sponsor's protocol ID: CV131-185
Status last verified: Aug 2008
First submitted: 5 Nov 2004
Last updated: 15 Apr 2011
Results posted: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension

All Hypertension trials

Study at a glance

From the registry record, last updated by the sponsor on 15 Apr 2011. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension
ClinicalTrials.gov ID: NCT00095550
Acronym / sponsor ID: CV131-185
Conditions: Hypertension
Keywords: Moderate Hypertension
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 496 participants (estimated)
Lead sponsor: Bristol-Myers SquibbIndustry (pharma, biotech, devices)
Collaborators: Sanofi
Study start: Oct 2004
Primary completion: Jun 2005 (actual)
Study completion: Jun 2005 (actual)
First posted: 8 Nov 2004 (estimated)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 3

Arm	Type	Receives
A1	Experimental	Drug: Irbesartan/HCTZ
A2	Active comparator	Drug: Irbesartan monotherapy
A3	Active comparator	Drug: HCTZ monotherapy

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

Willing to provide written informed consent
Subjects must have uncontrolled hypertension defined as:
Subjects must be willing to discontinue their antihypertensive medication, if applicable.
Men and women, ages 18 and older will be included.
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication.

Key exclusion criteria (13 listed)

Women who are pregnant or breastfeeding
Known or suspected secondary hypertension
Hypertension emergencies or stroke within the past 12 months.
Heart attack, angina or bypass surgery within the past six months.
Significant kidney disease

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Irbesartan/HCTZAlso: AvaproTablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.	Drug	A1
Irbesartan monotherapyAlso: AvaproTablets, Oral, 150 mg, Once daily, 12 weeks.	Drug	A2
HCTZ monotherapyTablets, Oral, 12.5 mg, Once daily, 12 weeks.	Drug	A3

Primary outcome

Change from baseline in SeSBP at Week 8

1 secondary outcome

Frequency of discontinuation due to AE, frequencies of hypotension, dizziness, syncope, headaches, hypokalemia and hyperkalemia after 12 weeks of therapy.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2011.

Related trials for Hypertension

Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Bristol-Myers Squibb study director

Bristol-Myers Squibb

128 sites in 5 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Irbesartan/HCTZ, Irbesartan monotherapy and HCTZ monotherapy in people with Hypertension, run by Bristol-Myers Squibb at 128 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Apr 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 128 sites in United States, Canada, Germany, France, Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in SeSBP at Week 8. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00095550.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2011.